Revvity AlphaLISA SureFire Biotin-Free Human IRF5 Aggregate Detection Kit, 500 assay points

Revvity Interferon regulatory factor 5 (IRF5) is a transcription factor involved in innate immunity and inflammatory responses, regulating the expression of type I interferons (IFN-alpha and IFN-beta) and pro-inflammatory cytokines. Activated by pattern recognition receptors such as Toll-like receptors (TLR), MDA5, or STING in response to viral infection, IRF5 plays a crucial role in antiviral defense. In its inactive form, IRF5 resides in the cytoplasm of uninfected cells. Upon activation, it undergoes phosphorylation, dimerization, and nuclear localization to drive gene expression. Dysregulation of IRF5 is linked to autoimmune diseases such as lupus and rheumatoid arthritis, as well as inflammatory cancers, where it modulates tumor-associated macrophages. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity The AlphaLISA SureFire Biotin-Free Human IRF5 Aggregate Detection Kit is a sandwich immunoassay for the quantitative detection of IRF5 aggregate in cellular lysates, using Alpha Technology. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity Formats: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

• The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
• The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
• The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
• The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

Revvity AlphaLISA SureFire Ultra kits are compatible with: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

• Cell and tissue lysates
• Antibody modulators
• Biotherapeutic antibodies

Revvity AlphaLISA SureFire Ultra kits can be used for: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

• Cellular kinase assays
• Receptor activation studies
• High-throughput screening for preclinical studies